The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.
 
Samuel John Harris
No Relationships to Disclose
 
Maria Jose de Miguel Luken
No Relationships to Disclose
 
Desamparados Roda Perez
No Relationships to Disclose
 
Raquel Perez Lopez
No Relationships to Disclose
 
Mona Parmar
No Relationships to Disclose
 
Vasanthi Prathapan
No Relationships to Disclose
 
Hasina Hassam
No Relationships to Disclose
 
Alison Joanne Turner
No Relationships to Disclose
 
Sonia Serrano Fandos
No Relationships to Disclose
 
Emma Hall
No Relationships to Disclose
 
Holly Tovey
No Relationships to Disclose
 
Nina Tunariu
No Relationships to Disclose
 
Juanita Suzanne Lopez
No Relationships to Disclose
 
Timothy Anthony Yap
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca; Clearbridge Biomedics; Vertex
Travel, Accommodations, Expenses - Janssen-Cilag; MSD Oncology; Vertex
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Udai Banerji
Research Funding - Chugai Pharma (Inst)